Supplementary Data Figure 1







Supplementary Data Figure 2



Supplementary Data Figure 3



Figure Legends Supplementary Data

Supplementary Data Figure 1. Expression of I2PP2A and CIP2A with siRNA knockdown. Neuroblastoma cells were treated with siRNA (20 nM) for I2PP2A, CIP2A, both together (dual), or negative control (siNeg) for 48 hours. A. With use of both I2PP2A and CIP2A siRNA together (siDual) there was a decrease in both proteins. B. Cells treated with siI2PP2A showed appropriate knockdown of I2PP2A without a compensatory increase in CIP2A. C. Cells treated with siCIP2A demonstrated appropriate decrease in CIP2A protein with no change in I2PP2A protein.

Supplementary Data Figure 2. FTY720 treatment increased protein phosphatase 2A activity. PP2A activity was measured in all four neuroblastoma cell lines following treatment with FTY720. Treatment with FTY720 (5 μM) for 4 hours resulted in a significant increase in PP2A activity in all four neuroblastoma cell lines (*$p \leq 0.02$). Experiments were repeated at least in triplicate and reported as mean ± SEM.

Supplementary Data Figure 3. FTY720 treatment did not affect ERK1/2 phosphorylation. SH-EP and WAC2 cells were treated with increasing concentrations of FTY720 for 24 hours. Immunoblotting of whole cell lysates did not show a significant change in ERK1/2 phosphorylation. Phosphorylation of ERK followed total ERK1/2 expression.